CSI Market
Sign In | Register

Humacyte Inc (HUMA) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access HUMA quarterly Cash Flow →
Observing cash flow movements over recent quarters helps explain how Humacyte Inc adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-40.83
Depreciation & amortization5.33
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability-59.47
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-21.83
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.01
Share-based Compensation9.75
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt22.27
Interest And Dividend Income Securities Held To Maturity-
Change In Fair Value Of Contingent Earnout Liability-
Operating Lease Cost-
Interest Expense Debt Excluding Amortization-
Gain On Paycheck Protection Program Loan Forgiveness Covid-
Finance Lease Right Of Use Asset Amortization2.02
Operating Lease Right Of Use Asset Amortization Expense0.04
Increase Decrease In Operating Lease Liability-0.04
Interest Expense Interest Bearing Liability9.11
Income taxes0.00
Unrealized Gain (Loss) on Derivatives-38.77
Increase (Decrease) in Accounts Receivable-0.26
Increase (Decrease) in Accounts Payable0.97
Increase (Decrease) in Accrued Liabilities-1.71
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense-0.53
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities8.90
Discontinued operations0.00
Net Cash flow from Operating Activities-105.04
Investing Activities
Capital Expenditures-0.88
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.88
Financing Activities
Short-term debt Net39.78
Other borrowing transactions-0.77
Long-term debt - borrowings-87.83
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock46.72
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net66.38
Initial Value Of Class A Common Stock Subject To Possible Redemption-
Finance Lease Principal Payments-2.75
Payments Of Transaction Costs-
Interest Expense Debt Revenue Interest-0.05
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities61.49
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-105.93
Total Cash Flow-44.44
4 historic quarters locked

Sign in to unlock the full Humacyte Inc cash flow history.

Sign In Create Free Account

About Humacyte Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001818382-26-000004

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License